Skip to content
Screener

Roivant Sciences ROIV Prepaid & Other Current

Prepaid & Other Current at other companies

Amgen logo
AmgenAMGN
$4.53B+32.2%
Moderna logo
ModernaMRNA
$124M-83.8%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$42.76M-16.4%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.22B-22.8%
AbbVie logo
AbbVieABBV
$150M-97.3%
Regenxbio logo
RegenxbioRGNX
$11.9M+10.5%

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$26.25B+244%
Enterprise value$26.28B+244%
P/S3,485×+3,157×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsCurrent.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0001635088-26-000090
Line itemJune 30, 2026March 31, 2026
Cash and cash equivalents$1,248,456$1,419,232
Marketable securities2,593,6262,872,601
Litigation settlement receivable771,627770,235
Other current assets128,371105,316
Total current assets4,742,0805,167,384
Property and equipment, net11,32011,986
Operating lease right-of-use assets78,88680,416
Investments measured at fair value444,622407,985

Item 1. Financial Statements (Unaudited).

FAQ

What is Roivant Sciences's prepaid & other current?
Roivant Sciences (ROIV) reported prepaid & other current of $128.37M in Q2 2026.
How has Roivant Sciences's prepaid & other current changed year-over-year?
Roivant Sciences's prepaid & other current increased by 14.0% year-over-year, from $112.6M to $128.37M.
What is the long-term trend for Roivant Sciences's prepaid & other current?
Over 5 years (2020 to 2025), Roivant Sciences's prepaid & other current has grown at a 14.2% compound annual growth rate (CAGR), from $54.25M to $105.32M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about Roivant Sciences's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude